Forte Biosciences is a healthcare company focused on developing innovative therapies for skin diseases. Its core products include treatments for atopic dermatitis and other dermatological conditions. The company primarily generates revenue through the commercialization of its therapeutic products and ongoing clinical trials aimed at expanding its product pipeline.
The investment profile of Forte Biosciences is more aligned with growth investors, given its focus on developing new therapies and potential for future revenue generation. The company currently does not offer dividends, and its financial performance indicates a higher risk profile. Investors may consider a medium to long-term horizon for potential value realization, with a moderate liquidity level suitable for those with basic to advanced experience in the market.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-08-27 | Sell | Hold | High volatility and negative EPS raise concerns. |
| 2026-08-11 | Hold | Sell | High volatility and negative EPS raise significant concerns. |
| 2026-08-09 | Sell | Hold | High volatility; uncertain fundamentals warrant caution. |
| 2026-07-30 | Hold | Sell | High volatility; uncertain fundamentals warrant caution. |
| 2026-07-28 | — | Hold | High volatility; uncertain fundamentals warrant caution. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-07-28 | Barclays | Update | — → 77 | 76.5 |
| 2026-07-27 | Evercore ISI | Rating Downgraded | — → 77 | 76.42 |
| 2026-07-21 | Barclays | Update | — → 74 | 47.49 |
| 2025-11-25 | Evercore ISI | Update | — → 65 | 19.06 |
